Evofem Biosciences Inc (OTCMKTS:EVFM) Stock In Focus After Appointing Interim Chief Financial Officer

March 10, 2023

On Thursday, Evofem Biosciences Inc (OTCMKTS:EVFM) was in the news after it made a key new appointment and the development could bring the stock into focus today. The company announced that it had appointed a new Interim Chief Financial Officer in the form of Albert Altro. Trading Data      On Thursday, EVFM stock slumped 17.45% to $0.0227 with more than 6.31 million shares, compared to volume of 2.40 million shares. The…

Read More >>

Evofem Biosciences Inc (OTCMKTS:EVFM) Stock Falls Following a Key Update

February 28, 2023

On Monday Evofem Biosciences Inc (OTCMKTS:EVFM) was in the news after it announced that two more United States patents had been listed for its product Plexxi. The two indications had also been labelled in the United States Food and Drug Administration publication named Approved Drug Products with Therapeutic Equivalence Evaluations, which is more colloquially known as the Orange Book. Trading Data On Monday, EVFM stock slumped 11.43% to $0.0310 with…

Read More >>

Evofem Biosciences Inc. (OTCMKTS:EVFM) Releases Results from Phase 3 EVOGUARD Clinical Trial

October 12, 2022

Evofem Biosciences Inc. (OTCMKTS:EVFM) announced updates on October 11, 2022, regarding the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women. Unfortunately, the trial didn’t accomplish its endpoints. Trading Data On Tuesday, EVFM stock decreased 4.71% to $0.1639 with more than 956.04K shares, compared to its average volume of 8.91 million shares. The stock moved within a range of $0.1611…

Read More >>